MedTrace Logo

Bupivacaine Supplementation For Postoperative Pain Control In Surgical Removal Of Mandibular Third Molars

NCT02353676 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-02-03

No results posted yet for this study

Summary

Control of postoperative pain is a foremost goal in achieving a satisfactory postoperative recovery. Surgical removal of lower third molars is accompanied by postoperative pain that is at its peak in the first 12 hours. Our study evaluates if the use of 2% lidocaine hydrochloride for the surgical removal of lower third molars with a postoperative 0.5% bupivacaine supplementation would result in lesser postoperative pain and a decrease in ingestion of oral analgesics to control the pain when compared to a placebo.

Conditions

  • Anesthesia, Local

Interventions

DRUG

Bupivacaine

1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia

OTHER

SALINE

1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.

Sponsors & Collaborators

  • Cosmozone Dental Clinic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-06-30
Completion
2015-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02353676 on ClinicalTrials.gov